Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-Help: dasatinib for relapsed or refractory T-follicular helper cell lymphoma
jRCT2031190079Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in T follicular helper cell lymphoma (TFHL), angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and 2 more, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Overall response rate. Started Nov 2019; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
T follicular helper cell lymphoma (TFHL)angioimmunoblastic T-cell lymphoma (AITL)follicular T-cell lymphoma (FTCL)T-cell lymphoma follicular helper (TFHL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2031190079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190079.